A groundbreaking study has unveiled a startling truth: primary glomerular diseases, once thought to be benign for young patients, can lead to severe kidney complications later in life. This revelation challenges conventional wisdom and highlights the urgent need for further research and treatment strategies.
The research, presented at ASN Kidney Week 2025, compared outcomes between adult and pediatric patients with primary glomerular diseases, including minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and IgA nephropathy (IgAN). By analyzing data from the CureGN study, a large-scale longitudinal cohort, the researchers discovered that children and young adults face similar or even higher risks of kidney function decline and progression to kidney failure compared to older adults.
For instance, pediatric patients with a biopsy-diagnosis of MCD experienced steeper declines in estimated glomerular filtration rate (eGFR) compared to adult patients with MCD. Similarly, MN patients aged 13-17 years and FSGS and IgA nephropathy patients aged 18-44 years showed the most rapid eGFR declines among their respective diagnosis groups. These findings suggest that the impact of primary glomerular diseases on kidney health is not limited to older age groups, and young patients may face a higher burden of disease over their lifetimes.
Lead author Margaret Helmuth, MS, from the University of Michigan, Ann Arbor, emphasized the significance of these findings, stating, "Young patients diagnosed with primary glomerular disease are at a significant risk of kidney failure and the need for dialysis or transplantation in their lifetimes. We believe future studies are crucial to understanding the lifetime impact and morbidity associated with these diseases in young patients."
Co-author Chia-shi Wang, MD, MSc, from the Emory University School of Medicine, added, "Our research underscores the importance of including children in clinical trials for disease treatment. By doing so, we can better address the adverse outcomes faced by this vulnerable population."
The study, titled "Glomerular Disease Outcomes Across the Lifespan: Report of the Cure Glomerulonephropathy (CureGN) Research Consortium," will be a focal point of discussion at Kidney Week 2025 in Houston, TX. This premier nephrology meeting brings together over 12,000 kidney professionals from around the globe to exchange knowledge, explore the latest advancements, and engage in thought-provoking discussions with leading experts in the field.
Join the conversation at #KidneyWk and be a part of this crucial dialogue on glomerular disease outcomes and the future of kidney health research and treatment.
